James E Flynn bought $25.0M of Larimar Therapeutics (LRMR)
Executed Feb 27, disclosed Mar 3, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -14.2% (delay-adjusted); from the execution session (Feb 27), -16.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
James E Flynn (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Larimar Therapeutics, Inc. (LRMR). Across 1 priced purchase filing, the average 21-session return was -16.6% from execution and -14.2% from disclosure (delay-adjusted; derived). The largest single filing was $70.9M of NUVL (742,574 sh across 2 lots, as filed), executed Nov 24 2025.
Healthcare · Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→9,375,000 sh across 3 lots
Exec Jul 31 2025
Filed Aug 4 2025 · 6:28 PM ET